Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This study observed that areas with low socio-demographic index showed the greatest rise in the disease burden of alopecia areata from 1990 to 2019, while high SDI areas still carried the highest burden overall.

In this analysis of two trials, baricitinib showed eyebrow and eyelash regrowth in severe alopecia areata patients with greater than 20% scalp hair loss at Week 36, compared to placebo.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

In this narrative review, researchers evaluated existing literature on the treatment of frontal fibrosing alopecia, finding that while no curative treatment exists, clinical improvements can be achieved through personalized and combined therapy approaches.

This source presents key guidelines for Alopecia areata treatment, recommending topical steroids and limited systemic treatments, and emphasizes the importance of hair replacement options, particularly advising against most systemic therapies in children and adolescents.

This guideline reports that corticosteroids are the only topical treatment for alopecia areata with a high recommendation level, while systemic corticosteroids and JAK inhibitors are recommended for adults.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

This review discusses the use of baricitinib in dermatology, emphasizing its effectiveness in treating certain dermatoses, while highlighting the need for awareness of its potential side effects and calling for more long-term safety data.

This study suggests that combining baricitinib with narrowband UV-B therapy is an effective and well-tolerated approach for treating active nonsegmental vitiligo.

In this study, the researchers used molecular docking to identify Erythrabyssin II from Erythrina subumbrans as a potential candidate for anti-alopecia treatment, comparable to minoxidil, suggesting clinical trials are needed to evaluate its pharmacological effects.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This article discusses the role of interleukin-15 and Janus kinase inhibitors in alopecia areata based on a murine model and reports no new experimental results.

In this narrative review, researchers outlined the role of T cells in the autoimmune pathogenesis of alopecia areata and highlighted ongoing research into therapeutic pathways, beyond current JAK inhibitors, aimed at developing new treatments for the disease.

This study observed that most pediatric dermatologists prefer class 1 and 2 topical corticosteroids as first-line treatments for pediatric alopecia areata, with increasing use of JAK inhibitors as second-line therapy.

In patients with alopecia areata, this study found elevated levels of venous thromboembolism markers SFMC and F1 + 2 compared to healthy controls, potentially indicating an increased risk for this condition.

This review discusses recent advances in the treatment of alopecia areata, highlighting new potential therapies like JAK inhibitors and PRP, and reports no new clinical results.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

This review discusses the niches supporting adult stem cells in various organisms, including well-studied germline niches and the less understood mammalian niches, but it reports no new research findings.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.

This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.

This review discusses recent therapeutic approaches for alopecia areata, including the use of Janus kinase inhibitors and interleukin-2, and reports no new clinical results.

This review summarizes recent research on alopecia areata, highlighting advances in targeted therapies due to improved understanding of its immunopathogenesis, though it reports no new clinical results.

This article reviews the differences in inflammatory processes between alopecia universalis and atopic dermatitis, focusing on type 1 and type 2 immune responses, but it reports no new results.

This case study reports that tofacitinib led to remission of psoriasis but did not improve alopecia universalis in one patient, suggesting varied responses in treating such conditions.

This study found that alopecia areata is linked to genetic factors, specifically HLA haplotypes on chromosome 6, and involves immune privilege collapse at hair follicles which is mediated by the JAK-STAT pathway and pro-inflammatory cytokines like IFN-γ.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.